P2Rx3 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The P2RX3 (Purinergic Receptor P2X Ligand-Gated Ion Channel 3) gene encodes a member of the P2X family of ATP-gated ion channels. P2X3 receptors are primarily expressed in sensory neurons and play crucial roles in pain sensation, taste transduction, and autonomic functions.
- Official Symbol: P2RX3
- Official Full Name: Purinergic Receptor P2X Ligand-Gated Ion Channel 3
- Chromosomal Location: 11q12.1
- Gene ID: 5024
- Protein: P2X3 Receptor
- UniProt: P56378
- OMIM: 602243
P2X3 receptors are trimeric ion channels composed of three identical subunits. Each subunit contains:
- N-terminal extracellular domain (~290 residues): Contains the ATP-binding site
- Two transmembrane domains (TM1 and TM2): Form the ion pore
- C-terminal intracellular domain (~30 residues): Important for channel regulation
The trimeric assembly creates a central pore that is permeable to Na⁺, K⁺, and Ca²⁺ ions. Each subunit contributes to the ATP-binding pocket located at the subunit interface.
The ATP-binding site is formed by:
- Orphan sites: Residues on adjacent subunits
- Phosphate-binding loop: Basic residues for ATP recognition
- Adenine recognition pocket: Hydrophobic residues for base binding
P2X3 receptors exhibit unique gating properties:
- Rapid response: Channel opens within milliseconds of ATP binding
- Low EC₅₀: High sensitivity to ATP (EC₅₀ ~1 μM)
- Voltage independence: Gating is largely voltage-independent
- Fast desensitization: Current decays within 100-200 ms
- Recovery: Slow recovery from desensitization (seconds)
- Cysteine-rich domain: Critical for desensitization kinetics
- ATP removal: Required for recovery
- Phosphorylation: PKC can modulate desensitization rates
P2RX3 encodes an ATP-gated ion channel:
- Ion channel: Rapidly permeable to Na⁺, K⁺, and Ca²⁺
- Fast desensitization: Quick response to ATP
- Pain signaling: Critical for nociceptor activation
- Taste transduction: Type III taste cells require P2X3
- Hetero-trimeric: Often forms heteromers (especially with P2X2)
P2X3 subunits readily form heterotrimeric channels with P2X2:
- Distinct properties: Different gating and pharmacology
- Slower desensitization: More sustained currents
- ATP sensitivity: Similar EC₅₀ values
- Distribution: Co-expressed in sensory neurons
P2RX3 is primarily expressed in sensory systems:
- Dorsal root ganglion (DRG): Small-diameter sensory neurons
- Trigeminal ganglion: Craniofacial pain receptors
- Nodose ganglion: Visceral sensory information
- Enteric nervous system: Gut sensory signaling
- Spinal cord dorsal horn: Pain transmission
- Brainstem: Autonomic integration
- Hippocampal interneurons: Modulatory role
- Taste buds: Type III receptor cells
- Airway epithelia: Chemosensing
- Urinary bladder: P2X3 in afferent signaling
P2X3 is a major contributor to chronic pain states:
Neuropathic Pain
- Nerve injury upregulates P2X3 expression
- Contributes to allodynia and hyperalgesia
- ATP release from damaged cells activates P2X3
Inflammatory Pain
- P2X3 sensitization via inflammatory mediators
- Cytokine modulation of channel function
- Therapeutic target for inflammatory conditions
Migraine
- Trigeminal P2X3 involvement
- CGRP-P2X3 interactions
- Meningeal nociceptor activation
Visceral Pain
- Gut-pain signaling via P2X3
- Irritable bowel syndrome (IBS)
- Bladder pain syndrome
P2X3 is essential for sour taste transduction:
- Ageusia: Complete loss of taste
- Dysgeusia: Distorted taste perception
- Type III cells: Require P2X3 for signaling
P2X3 alterations in AD:
- Sensory signaling changes: Altered pain perception
- Calcium dysregulation: P2X3-mediated Ca²⁺ influx
- Therapeutic potential: P2X3 as drug target
- Neuroinflammation: ATP-P2X3 signaling in glia
P2X3 in PD:
- Non-motor symptoms: Sensory dysfunction
- Olfactory impairment: Possible role in smell loss
- Pain: PD-related pain mechanisms
P2X3 is a major drug target, especially for pain:
First-Generation
- PPADS: Non-selective P2 antagonist
- Suramin: Broad P2X antagonist
Selective Antagonists
- A-317491: First selective P2X3 antagonist
- AF-353 (RO-4): Highly selective
- AF-942: Improved potency
- BL-5529: Clinical candidate
- Chronic cough: Gefapixant (BL-4740) — FDA approved
- Overactive bladder: Resiniferatoxin trials
- Neuropathic pain: Phase II trials ongoing
- Migraine: P2X3-targeting approaches
- Peripheral targets: Reduced CNS side effects
- Non-opioid mechanism: No addiction potential
- Disease modification: May address underlying pathology
P2RX3 knockout mice have provided crucial insights:
- Pain responses: Deficient inflammatory and neuropathic pain
- Taste: Impaired sour taste perception
- Viability: Viable and fertile
- Behavior: Normal development and locomotion
P2X3 interacts with various proteins and signaling pathways:
- P2X2: Heteromeric channel formation
- P2X5: Possible heteromers in some tissues
- P2X7: Cross-talk in pain signaling
- PKC: Modulates desensitization
- ATP: Primary agonist
- Adenosine: Antagonistic effects
- CGRP: Co-release in trigeminal system
- TRPV1: Functional interactions
- Sodium channels: Nav1.7, Nav1.8
The study of P2Rx3 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.